publication . Article . Other literature type . 2017

The implementation of managed entry agreements in Central and Eastern Europe : findings and implications

Diāna Arāja; Maciej Pomorski; Ieva Greičiūtė-Kuprijanov; Tanja Novakovic; Maria Dimitrova; Jurij Fürst; Luka Voncina; Tomasz Bochenek; Brian Godman; Olga Löblová; ...
Open Access English
  • Published: 01 Dec 2017
Abstract
Background Managed entry agreements (MEAs) are a set of instruments to facilitate access to new medicines. This study surveyed the implementation of MEAs in Central and Eastern Europe (CEE) where limited comparative information is currently available. Method We conducted a survey on the implementation of MEAs in CEE between January and March 2017. Results Sixteen countries participated in this study. Across five countries with available data on the number of different MEA instruments implemented, the most common MEAs implemented were confidential discounts (n = 495, 73%), followed by paybacks (n = 92, 14%), price-volume agreements (n = 37, 5%), free doses (n = 2...
Subjects
free text keywords: RS, Original Research Article, RZ Other systems of medicine, Health administration, Transparency (graphic), MEDLINE, Confidentiality, Health economics, Brand names, Family medicine, medicine.medical_specialty, medicine, Public health, Public administration, Payment, media_common.quotation_subject, media_common, business.industry, business
49 references, page 1 of 4

Ferrario, A, Kanavos, P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med.. 2014; 124: 39-47 [OpenAIRE] [PubMed] [DOI]

Howard, DHBP, Berndt, ER, Conti, RM. Pricing in the market for anticancer drugs. J Econ Perspect.. 2015; 29 (1): 139-162 [OpenAIRE] [PubMed] [DOI]

3.WHO. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. http://www.euro.who.int/__data/assets/pdf_file/0008/306179/Access-new-medicines-TR-PIO-collaboration-research.pdf?ua=1. Accessed 22 Feb 2017.

Carlson, JJ, Sullivan, SD, Garrison, LP, Neumann, PJ, Veenstra, DL. Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between health care payers and manufacturers. Health Policy.. 2010; 96 (3): 179-190 [OpenAIRE] [PubMed] [DOI]

5.Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. Brussels, Belgium: EMiNet. 2013. http://eprints.lse.ac.uk/50513/1/__Libfile_repository_Content_Ferrario%2C%20A_Ferrario_Managed_%20entry_%20agreements_2013_Ferrario_Managed_%20entry_%20agreements_2013.pdf. Accessed 22 Feb 2017.

Garrison, LJ, Towse, A, Briggs, A, de Pouvourville, G, Grueger, J, Mohr, P. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health.. 2013; 16 (5): 703-719 [OpenAIRE] [PubMed] [DOI]

Hollis, A. Sustainable financing of innovative therapies: a review of approaches. PharmacoEconomics.. 2016; 34 (10): 971-980 [OpenAIRE] [PubMed] [DOI]

8.Carlson J, Chen S, Garrison LP Jr. Performance-based risk-sharing arrangements: an updated international review. Pharmacoeconomics. 2017. doi:10.1007/s40273-017-0535-z.

Lu, C, Lupton, C, Rakowsky, S, Babar, Z, Ross-Degnan, D, Wagner, A. Patient access schemes in Asia-pacific markets: current experience and future potential. J Pharm Policy Pract.. 2015; 8 (1): 6 [OpenAIRE] [PubMed] [DOI]

Jarosławski, S, Toumi, M. Design of patient access schemes in the UK: influence of health technology assessment by the National Institute for Health and Clinical Excellence. Appl Health Econ Health Policy.. 2011; 9 (4): 209-215 [OpenAIRE] [PubMed] [DOI]

Jaroslawski, S, Toumi, M. Market access agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts. BMC Health Serv Res.. 2011; 11 (1): 259 [OpenAIRE] [PubMed] [DOI]

Towse, A, Garrison, LP. Can’t get no satisfaction? Will pay for performance help? toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics.. 2010; 28 (2): 93-102 [OpenAIRE] [PubMed] [DOI]

Garrison, LJ, Carlson, J, Bajaj, P, Towse, A, Neumann, P, Sullivan, S. Private sector risk-sharing agreements in the United States: trends, barriers, and prospects. Am J Manag Care.. 2015; 21 (9): 632-640 [PubMed]

Garrison, LP, Towse, A. Toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Value Health.. 2009; 12 (7): A488 [OpenAIRE] [DOI]

Adamski, J, Godman, B, Ofierska-Sujkowska, G, Osinska, B, Herholz, H, Wendykowska, K. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res.. 2010; 10: 153 [OpenAIRE] [PubMed] [DOI]

49 references, page 1 of 4
Any information missing or wrong?Report an Issue